Tadalafil interactions are not limited to erectile-dysfunction pills. As a PDE5 inhibitor with systemic vasodilating effects, tadalafil can cause dangerous hypotension when taken with organic nitrates or guanylate-cyclase stimulators such as riociguat. Those combinations are contraindicated in U.S. labeling. Other medicines require individualized evaluation because they can change blood pressure, tadalafil concentrations or both.
The interaction review must cover the entire medication list: prescription drugs, occasional chest-pain sprays, products used for urinary symptoms, antifungals, selected antibiotics, antivirals and supplements. Tadalafil is mainly metabolized through CYP3A4, so strong inhibitors or enzyme inducers can change exposure. A medication change that occurs after the initial ED prescription can create a new problem.
This is the cross-class interaction hub rather than a dosing calculator. The most consequential nitrate risk is covered separately in tadalafil and nitrates. For alcohol-specific orthostatic effects use the alcohol guide. Never stop a prescribed cardiovascular medicine to enable tadalafil without clinician guidance.
Organic nitrates used for angina or other cardiovascular reasons can intensify tadalafil-related blood-pressure lowering. Examples include nitroglycerin in various forms and longer-acting nitrate prescriptions. Riociguat, used in certain pulmonary-hypertension settings, is another contraindicated combination because it stimulates the same downstream signaling system.
The danger depends on actual exposure, not on whether a patient currently feels dizzy. A person taking these medicines must not substitute a different tablet schedule or guess a waiting period as a workaround. Chest-pain emergencies require professional treatment and disclosure of recent tadalafil use.
Alpha blockers such as doxazosin or tamsulosin may be prescribed for urinary symptoms or other conditions. When used with tadalafil, blood-pressure effects can become more pronounced, although the level of interaction varies by agent and clinical setting. Some patients may need a revised treatment approach or close review by the prescriber.
The Cialis label specifically does not recommend combining tadalafil with alpha blockers for treating BPH because of blood-pressure risk and incomplete supporting efficacy evidence. ED treatment in a patient already taking an alpha blocker involves a different assessment, not automatic authorization.
Tadalafil is metabolized predominantly by CYP3A4. Potent inhibitors such as ketoconazole or ritonavir can increase exposure enough to trigger specific U.S. label limits: for as-needed ED use, the maximum is 10 mg no more often than every 72 hours; for once-daily tadalafil, the maximum is 2.5 mg. These are clinician-applied interaction restrictions, not recommendations for readers to adjust their own tablets.
Short courses of antifungals, certain antibiotics or new HIV-treatment regimens may introduce or change this interaction. For other CYP3A4 inhibitors, assessment depends on the actual agent and labeling; not all have identical effects. Report medications started after the tadalafil prescription and ask for a pharmacist/prescriber review before further use.
Rifampin and other enzyme-inducing medicines can decrease exposure to tadalafil. This is an efficacy concern rather than the same mechanism as nitrate-associated dangerous hypotension. A lower response in that context does not mean a user should take more tablets.
A clinician may decide to reevaluate the entire treatment or manage the interacting medicine differently. A complete history avoids mistaking a pharmacokinetic interaction for a newly ineffective brand.
The table deliberately separates combinations prohibited by labeling from circumstances requiring clinical review. An example in the table is not a comprehensive list of every medicine in a class, and an unlisted drug is not automatically safe.
Use the exact generic and brand names on prescription labels. When names are unfamiliar, ask a pharmacist to determine the ingredients before tadalafil is dispensed.
| Category | Examples or context | Clinical significance |
|---|---|---|
| Organic nitrates | Nitroglycerin, isosorbide medicines | Contraindicated: severe hypotension risk |
| GC stimulators | Riociguat | Contraindicated |
| Alpha blockers | Tamsulosin, doxazosin | Blood-pressure effects; indication-specific cautions |
| CYP3A4 inhibitors | Certain azole antifungals, antivirals | Potential increase in tadalafil exposure |
| CYP3A4 inducers | Rifampin and related drugs | Potential decrease in tadalafil exposure |
| Other blood-pressure therapies | Individual antihypertensives | Review additive effects and symptoms |
| Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) | Increased tadalafil exposure | As-needed: max 10 mg once per 72 hours; once daily: max 2.5 mg, under prescriber supervision |
Clinical studies found modest additional blood-pressure reductions with some commonly used antihypertensives when coadministered with tadalafil. That does not mean every combination is forbidden, nor does it establish safety without knowing a patient’s baseline pressure and cardiovascular status.
A patient with multiple blood-pressure drugs, recurrent dizziness or a recent cardiac event deserves particular evaluation. Severe hypotension symptoms require medical attention rather than experimentation with spacing or skipping prescribed cardiovascular medicines.
Adding sildenafil, vardenafil or another PDE5 inhibitor is not an evidence-based way to make tadalafil stronger. U.S. labeling does not establish the safety of combinations of tadalafil with other PDE5 inhibitors or ED treatments, and a greater blood-pressure effect is possible.
Even if products are sold under different brand names, their ingredients may overlap. The ED medication directory distinguishes ingredient families and why product-name differences do not justify simultaneous use.
Once-daily tadalafil leads to relatively continuous exposure. A short course of an interacting medication may overlap multiple daily doses. As-needed administration has different timing, but its long half-life means interactions are not confined to the hour of ingestion.
The label limits are not identical across regimens: with potent CYP3A4 inhibition, as-needed use has a 10 mg/72-hour ceiling while once-daily use has a 2.5 mg ceiling. Severe renal impairment may also make daily use unsuitable. The schedule comparison explains why daily and occasional exposure differ, while the dosage page handles the wider prescribing framework.
When someone has chest pain or another cardiovascular emergency, the treating team needs the exact ED medicine, prescribed regimen and most recent administration. This is essential because nitrate medicines commonly used in heart care are contraindicated with tadalafil and should not be self-administered in this situation.
Seeking emergency assessment is safer than deciding that enough hours have passed. The precise management of life-threatening angina in a person exposed to tadalafil belongs to monitored emergency care, not instructions from an internet article.
Bring a complete list including nonprescription products, recent short courses, chest-pain medications, urinary-symptom treatment and any ED drugs obtained elsewhere. Ask the pharmacist to reconcile brand and generic names and notify the prescriber of possible contraindications or regimen-specific warnings.
For broader information about how medicines are evaluated before issue, see tadalafil prescription requirements. This page does not choose a dose or recommend discontinuing a necessary medicine.
No. Organic nitrates and tadalafil are contraindicated because of the risk of a dangerous reduction in blood pressure.
No. Concomitant use with riociguat and other guanylate-cyclase stimulators is contraindicated.
Alpha blockers may add to blood-pressure lowering; the precise concern depends on the drug and indication. A clinician must review the combination.
Yes. Strong CYP3A4 inhibitors such as ketoconazole can increase tadalafil exposure. The U.S. label sets different limits for as-needed use (no more than 10 mg every 72 hours) and once-daily use (no more than 2.5 mg). Only the prescriber should apply those limits.
Rifampin can substantially reduce tadalafil exposure. Do not compensate by taking extra tablets; seek prescribing advice.
Do not combine PDE5 inhibitors unless an appropriately qualified clinician has specifically evaluated the combination; safety and suitability cannot be assumed.
Not always. Effects differ by drug and medical context, but nitrates and riociguat are specifically contraindicated.
Tell them that you use tadalafil, which regimen was prescribed and when you most recently took it, especially when chest pain is involved.